Biotech Sector Rallies Amidst AI Advances Despite Lackluster Fund Flows
The biotechnology sector is experiencing a resurgence, driven by late-stage trial successes like Moderna's mRNA melanoma vaccine and broader tailwinds from consolidation, cancer drug development, and artificial intelligence. While the rally has pushed key ETFs to levels not seen since the height of the pandemic, fund inflows remain modest compared to 2020. Analysts suggest that healthcare is slowly regaining investor interest after years of outflows. Despite underwhelming flows into biotech funds in 2026—such as a $361 million net inflow for iShares Biotechnology ETF (IBB)—the sector's strong performance has outpaced the S&P. The SPDR S&P Biotech ETF (XBI) and IBB have gained over 33% and nearly 24%, respectively, this year. Healthcare is also benefiting from AI advancements in drug development, though analysts caution that these benefits are still emerging. As valuations remain attractive with little exuberance in positioning, the sector may be poised for a sustained rally.
Topics: biotechnology ETF flows investor behavior stock market